Compounded vs Brand GLP-1
How compounded and brand-name GLP-1 medications differ, when compounding is legitimate, and the red flags that signal a risky clinic.
What is the difference between compounded and brand-name GLP-1 medication?
What exactly is a compounded GLP-1 medication?
Compounding is when a licensed pharmacy prepares a medication by combining or altering ingredients for a patient. It is a legitimate, long-standing part of pharmacy practice, used for things like adjusting a dose or removing an allergen. Compounded semaglutide and tirzepatide are made this way rather than by the drug's manufacturer.
The single most important fact about them is this: no compounded drug is FDA-approved. The FDA does not review compounded semaglutide or tirzepatide for safety, effectiveness, potency, or purity. That does not automatically make it dangerous, but it does mean the quality-control safety net that exists for Wegovy or Zepbound is not there. Some compounded products also use a different salt form of the drug than the approved version.
How do 503A and 503B pharmacies differ?
Not all compounding pharmacies are the same, and the distinction is central to whether a compounded product is coming from a credible source.
| Type | Primary oversight | What it does |
|---|---|---|
| 503A | State boards of pharmacy | Compounds patient-specific prescriptions |
| 503B outsourcing facility | Registers with and is inspected by the FDA | Compounds larger batches under tighter manufacturing standards |
Neither type produces an FDA-approved drug. But a 503B facility operates under more federal oversight and FDA inspection, while a 503A pharmacy is regulated mostly at the state level. A clinic that can tell you which type of pharmacy fills its prescriptions, and name it, is being far more transparent than one that will not.
Why does compounded GLP-1 exist at all?
Two reasons. First, cost: compounded semaglutide often runs a few hundred dollars a month versus well over a thousand for brand-name product. Second, and more importantly for the law, shortages. When the FDA lists a drug as being in shortage, compounding pharmacies gain more room to prepare copies of it. Brand-name semaglutide and tirzepatide were on the FDA shortage list, and that is what drove the wave of compounded GLP-1 offerings.
The flip side matters just as much: as the FDA declares those shortages resolved, the legal basis for compounding these specific drugs narrows, and legitimate supply tightens. A clinic still pushing cheap compounded GLP-1 as though nothing has changed is a signal to slow down and ask where the product is actually coming from.
What separates legitimate sourcing from gray-market sourcing?
The difference is not the word "compounded." It is the chain of accountability behind the medication.
| Legitimate | Gray-market red flag |
|---|---|
| Named, licensed prescriber writes the prescription | No named prescriber; buy-it-now checkout |
| Real clinical evaluation before prescribing | Prescription issued with no evaluation, or a rubber-stamp form |
| Dispensing pharmacy named; 503A/503B disclosed | Pharmacy hidden or vague; 'partner pharmacy' with no name |
| States plainly the product is not FDA-approved | Implies FDA approval or calls it 'the same as' Wegovy/Zepbound |
| Sold as a prescription medication | Sold as a 'research chemical' or 'not for human consumption' |
That last row is the brightest line. Anything marketed as a research chemical, a research peptide, or "not for human consumption" is not legitimate medical care, and no legitimate clinic frames a GLP-1 that way.
What red flags should make you walk away?
- No named, verifiable prescriber.
- A prescription issued with no real evaluation of your health history.
- Hidden or unnamed medication sourcing, or no named dispensing pharmacy.
- Compounded product described as equivalent to, or implying, FDA approval.
- "Guaranteed approval," "everyone qualifies," or a checkout that sells before it evaluates.
- Weight-loss guarantees or "no diet or exercise needed" marketing.
- No follow-up plan and no way to report a side effect.
How does GLP-1 Grades treat compounded sourcing?
Our grading does not penalize a clinic simply for using compounded medication. Plenty of legitimate providers do, especially where cost is a barrier. What we grade is transparency and oversight. Medication sourcing is one of the two heaviest dimensions in our rubric: a clinic earns credit for disclosing brand versus compounded, naming the dispensing pharmacy, disclosing 503A versus 503B status, and stating plainly that compounded product is not FDA-approved.
The caps are where sourcing gets punished. A clinic with hidden or undisclosed sourcing is capped low. A clinic that describes compounded product as equivalent to, or implying, FDA approval fails outright, as does one selling GLP-1s framed as research chemicals. See the full rubric on our methodology page, and compare graded clinics to see how real providers score. If you are choosing between the drugs themselves, our semaglutide and tirzepatide guides cover each in depth.
This guide is informational and is not medical advice or legal advice. It does not recommend taking any medication. Verify a clinic's prescriber credentials and pharmacy sourcing directly, and make decisions with a licensed healthcare provider who knows your history.